Loading...
Loading...
DNLI| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 129.8M |
| Operating I/L | -129.8M |
| Other Income/Expense | 15.2M |
| Interest Income | 15.2M |
| Pretax | -114.7M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -114.8M |
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutic candidates for neurodegenerative diseases. The company's primary product candidates include LRRK2 inhibitor BIIB122/DNL151 for Parkinson's disease, DNL310 for hunter syndrome, DNL343 for amyotrophic lateral sclerosis (ALS), AR443820/DNL788 for ALS, multiple sclerosis (MS), and Alzheimer's disease, and SAR443122/DNL758 for cutaneous lupus erythematosus. Denali Therapeutics Inc. generates revenue through the development and commercialization of these therapeutic candidates, as well as through collaboration agreements with pharmaceutical companies and research partnerships in the field of neurodegenerative diseases.
